ALK+ Metastatic Non-Small Cell Lung Cancer: The Importance of Biomarker Testing

February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.

Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews

Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

The addition of smoking status to the National Cancer Database might inform more effective treatment for smokers with cancer.